Diapositivo 1 - PowerPoint PPT Presentation

About This Presentation
Title:

Diapositivo 1

Description:

FINANCIAL DISCLOSURES The authors have no financial interest in the subject matter of this poster. – PowerPoint PPT presentation

Number of Views:20
Avg rating:3.0/5.0
Slides: 13
Provided by: Ana9a
Category:

less

Transcript and Presenter's Notes

Title: Diapositivo 1


1
FINANCIAL DISCLOSURES
The authors have no financial interest in the
subject matter of this poster.
2
CATARACT SURGERY IN PATIENTS ON WARFARIN THERAPY
HAEMORRHAGIC COMPLICATIONS AND POSTOPERATIVE
VISUAL ACUITY
Paulo Silva Guerra MD, Walter Rodrigues MD, David
Lopes MD, Lurdana Gomes MD, M. Monteiro Grillo MD
Ophthalmology Department. Director Prof. Dr. M.
Monteiro Grillo Hospital de Santa Maria (HSM) /
Lisbon - Portugal
3
Introduction
  • Traditionally, warfarin has been discontinued
    prior to cataract surgery because of concerns
    about increased risk of hemorrhagic complications
  • The trend amongst surgeons has shifted strongly
    towards continuation of anticoagulation
  • Recent surveys indicates the majority (?70) of
    surgeons keep cataract patients anticoagulated.5

Purpose
  • To assess ophthalmic complications associated
    with cataract surgery under topical anesthesia in
    patients on warfarin therapy.

4
Material and Methods
  • Retrospective review of 49 eyes of 42 patients
    on warfarin therapy (Warfarin Group).
  • Undergoing cataract surgery by
    phacoemulsification and IOL placement with
    topical anesthesia.
  • We evaluate
  • - The rates of intraoperative hemorrhagic
    complications of the anterior and posterior
    segment
  • - The rates of postoperative hemorrhagic
    complications of the anterior and posterior
    segment
  • - The pre and postoperative Best Corrected
    Visual Acuity (BCVA)

5
Material and Methods
  • The results of are compared with a control
    group, not anticoagulated (age and surgeon
    matched).
  • All cataract surgeries were performed by three
    experienced surgeons from January 2008 to June
    2009

6
Results
Demographics
Warfarin Group Control Group
Patients 42 51
Eyes 49 60
Mean age 75,3 (SD7,1) 78,7 (SD7,9)
Gender ? - 18 (43) ? - 21 (41)
Preoperative BCVA 0,49 (SD1,86) 0,56(SD2,02)
  • Intraoperative non-hemorrhagic complications
  • Warfarin Group - 2 posterior capsule ruptures
  • Control Group - 3 posterior capsule ruptures

7
Results
Intraoperative Hemorrhagic Complications
Warfarin Group n49 Control Group n60
Subconjunctival hemorrhage 0 0
Hyphema 2 (4,1) 0 P 0,11
Suprachoroidal hemorrhage 0 0
8
Results
Postoperative Hemorrhagic Complications
Warfarin Group n49 Control Group n60
Subconjuntival H. 6 (12,2) 1 (1,7) P 0,02
Hyphema 2 (4,1) 0 P 0,11
Vitreous Hemorrhage 0 0
Suprachoroidal H. 0 0
Retinal Hemorrhages 4 (8,1) 5 (8,3) P 0,9
9
Results
Postoperative BCVA
Warfarin Group n49 Control Group n60
BCVA 0,81 0,84 P 0,58
SD 0,25 0,24
Variation 0,2-1 0,3-1
10
Discussion
  • Subconjuntival Hemorrhage
  • - Most frequent hemorrhagic complication in
    Warfarin Group
  • - The only statistically significant (Plt0,05)
  • There was no statistically significant
    difference in the other hemorrhagic complication
    between the 2 groups (Pgt0,05).
  • There was no statistically significant
    difference in postoperative BCVA between the 2
    groups (Pgt0,05).

11
Conclusions
  • Continuation of treatment with warfarin in
    patients undergoing phacoemulsification and IOL
    placement with topical anesthesia is safe and was
    not associated with increased risk of vision
    threatening complications.

12
References
1. Katz J, Feldman MA, Bass EB, Lubomski LH,
Tielsch JM, Petty BG et al. Risks and benefits of
anticoagulant and antiplatelet medication use
before cataract surgery. Ophthalmol. 2003. 110
1784-1788 2. Barequet IS, Sachs D, Priel A,
Wasserzug Y, Martinowitz U, Moisseiev J et
al. Phacoemulsification of cataract in patients
receiving Coumadin therapy  ocular
and hematologic risk assessment. Am J Ophthalmol.
2007 Nov144(5) 719-23 3. Morris A, Elder MJ.
Warfarin therapy and cataract surgery. Clin
Experiment Ophthalmol. 2000 Dec28(6)419-22 4.
Carter K, Miller KM. Phacoemulsification and lens
implantation in patients treated with aspirin or
warfarin. J Cataract Refract Surg. 1998 Oct
24(10)1361-4 5. Ong-Tone L, Paluck EC,
Hart-Mitchell RD. Perioperative use of warfarin
and aspirin in cataract surgery by Canadian
Society of Cataract and Refractive Surgery
members survey. 2005 May31(5)991-6 6. Stone
LS, Kline OR, Sklar C. Intraocular lenses and
anticoagulation and anti-platelet therapy. Am
Intra-Ocular Implant Soc J. 198511165-68 7.
Jonas JB, Pakdaman B, Sauder G. Cataract surgery
under systemic anticoagulation therapy with
coumarin. Eur J Ophthalmol 2006 1630-32 8.
Rotenstreich Y, Rubowitz A, Segev F et al. Effect
of warfarin therapy on bleeding during cataract
surgery. J Cataract Refract Surg 2001271344-46
Write a Comment
User Comments (0)
About PowerShow.com